Lupus News

MADRID — Ten-year follow-up data for a cohort of patients with systemic lupus erythematosus who received belimumab showed that the drug maintained efficacy and tolerability, according to findings presented at the EULAR Annual Congress.

MADRID — Patients with lupus nephritis who were treated with a voclosporin-based combination therapy met all primary and secondary endpoints, including durable complete remission, according to findings presented at the EULAR Annual Congress.

Sexual dysfunction and intimacy issues may rank high among the complaints reported by patients with rheumatic diseases, but these complaints often remain unaddressed in the clinical setting, for several reasons. Poor communication between physicians and patients is the most likely explanation, along with poor communication between patients and their partners. However, the reasons for this communication gap, which may range from stigma to time constraints in the clinic, are up for debate.

Pulmonary embolism was associated with lupus, according to results of a recently published retrospective study.

Long-term use of hydroxychloroquine and low-dose aspirin use led to fewer cardiovascular events in patients with lupus, according to a recently published analysis.

For patients with systemic lupus erythematosus, researchers of this study found the Patient Reported Outcomes Measurement Information System Computerized Adaptive Test correlated with findings from the SF-36 and Lupus Quality of Life Tests and showed fewer floor and ceiling effects.

Compared with children in the general population, more children with systemic lupus erythematosus had BK viremia and viruria, according to results of this prospective cohort study.

In a recently published observational study, patients with lupus who did not have a history of kidney disease rarely got kidney disease during pregnancy.

DESTIN, Fla. — Despite the challenges of drug development for the treatment of systemic lupus erythematosus, there are reasons for optimism about the future, according to a speaker at the Congress of Clinical Rheumatology Annual Meeting.

Compared with placebo, treatment with mycophenolate was linked with improvements in physiologic measures and dyspnea in patients with systemic sclerosis-related interstitial lung disease, according to recently published data.